
Denali's Hunter syndrome therapy gets priority review; LENZ inks Canada deal
Denali gets priority review for rare disease therapy: The program, called tividenofusp alfa, is designed to treat Hunter syndrome, a protein misfolding disease that begins …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.